A recent study concludes that both hypertension and proteinuria, which are considered to be interrelated with the pharmacological action of bevacizumab, have the potential to indicate greater likelihood of therapeutic efficacy.
Bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF) treatment, can be used in combination with paclitaxel to treat advanced breast cancer, but hypertension and proteinuria are characteristic adverse events (AEs) associated with bevacizumab therapy. A proposed mechanism underlying bevacizumab-induced hypertension is the inhibition of VEGF, which results in decreased production of the vasodilator nitric oxide. Development of proteinuria has also been attributed to VEGF inhibition, which can decrease glomerular filtration and lead to protein leakage into urine.
A recent study in Japanese patients with breast cancer investigated whether these AEs could serve as predictors of treatment response to bevacizumab, and found that patients who developed hypertension and proteinuria early in their therapy had a stronger antitumor response.
The retrospective study, published in the Biological and Pharmaceutical Bulletin, included 19 patients with advanced, recurrent breast cancer treated in a single center in Japan between May 2012 to January 2016. Patients were observed from the beginning of therapy to 8 weeks after. During the observation period, 7 patients developed hypertension during the study period, while 12 did not; 7 patients developed proteinuria, and 12 did not.
No patients achieved a complete response, but in the group that developed hypertension, 100% achieved a partial response (PR), while 33.3% of the non-hypertensive group achieved a PR. Similarly, 100% of the group who developed proteinuria and 33.3% of the group who did not achieved a PR. According to the authors, these findings demonstrate a significantly stronger antitumor response in the 2 AE groups (P <.05).
Median progression-free survival (PFS) in the groups with and without hypertension were 355 days versus 147 days, respectively; median PFS for patients with and without proteinuria were 504 days versus 173 days, respectively.
The authors conclude that both hypertension and proteinuria, which are considered to be interrelated with the pharmacological action of bevacizumab, have the potential to indicate greater likelihood of therapeutic efficacy.
In order to control these AEs so that therapy can continue, say the authors, patients may need to be given appropriate antihypertensive medication. Proteinuria can, when of a high grade, require discontinuation of bevacizumab; however, the authors say that patients may continue to benefit from bevacizumab even after treatment discontinuation.
Reference
Tanaka H, Takahashi K, Yamaguchi K, et al. Hypertension and proteinuria as predictive factors of effects on bevacizumab on advanced breast cancer in Japan. Biol Pharm Bull. 2018;41(4):644-648. doi: 10.1248/bpb.b17-00605.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.